Bisphosphonates induced osteonecrosis of the jaw의 기전, 예방, 위험 평가 및 치료 방법

참고문헌 (50)

1. Epstein S, "Update of current therapeutic options for the treatment of postmenopausal osteoporosis", Clin Ther, 28, pp.151~173 (2006)
2. Badros A, "Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors", J Clin Oncol, 24, pp.945~952 (2006)
3. Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases", J Oral Maxillofac Surg, 62, pp.527~534 (2004)
4. Berenson JR, "American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma", J Clin Oncol, 20, pp.3719~3736 (2002)
5. Owens G, "An integrated approach: bisphosphonate management for the treatment of osteoporosis", Am J Manag Care, 13(11), pp.S290~S308 (2007)
6. Brooks JK, "Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103, pp.780~786 (2007)
7. Wynn RL, "Oral bisphosphonates and osteonecrosis of the jaw", Gen Dent, 55, pp.8~10 (2007)
8. Marx RE, "Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
9. Migliorati CA, "Bisphosphanates and oral cavity avascular bone necrosis", J Clin Oncol, 21, pp.4253~4254 (2003)
10. Khosla S, "Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
11. Bamias A, "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors", J Clin Oncol, 23, pp.8580~8587 (2005)
12. Grbic JT, "Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial", J Am Dent Assoc, 139, pp.32~40 (2008)
13. Bilezikian JP, "Osteonecrosis of the jaw--do bisphosphonates pose a risk?", N Engl J Med, 355, pp.2278~2281 (2006)
14. Boonyapakorn T, "Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies", Oral Oncol, 44, pp.857~869 (2008)
15. Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia", J Oral Maxillofac Surg, 65, pp.415~423 (2007)
16. Black DM, "Once-yearly zole dronic acid for treatment of postmenopausal osteoporosis", N Engl J Med, 356, pp.1809~1822 (2007)
17. Etminan M, "Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study", J Rheumatol, 35, pp.691~695 (2008)
18. Cartsos VM, "Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people", J Am Dent Assoc, 139, pp.23~30 (2008)
19. Edwards BJ, "Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on ScientificAffairs", J Am Dent Assoc, 139, pp.1674~1677 (2008)
20. Sedghizadeh PP, "Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry", J Am Dent Assoc, 140, pp.61~66 (2009)
21. Fleisch H, "Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis", Nature, 212, pp.901~903 (1966)
22. Fleisch H, "Development of bisphosphonates", Breast Cancer Res, 4, pp.30~34 (2002)
23. Green JR, "Bisphosphonates: preclinical review", Oncologist, 9(4), pp.3~13 (2004)
24. "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws", J Oral Maxillofac Surg, 65, pp.369~376 (2007)
25. Rogers MJ, "Cellular and molecular mechanisms of action of bisphosphonates", Cancer, 88, pp.2961~2978 (2000)
26. Benford HL, "Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs", Mol Pharmacol, 56, pp.131~140 (1999)
27. Bergstrom JD, "Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase", Arch Biochem Biophys, 373, pp.231~241 (2000)
28. Lehenkari PP, "Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP", ATP translocase by a nonhydrolyzable, adenine-containing metabolite, 2002, pp.61, 1255~1262
29. McClung MR, "Bisphosphonates", Endocrinol Metab Clin North Am, 32, pp.253~271 (2003)
30. Alakangas A, "Alendronate disturbs vesicular trafficking in osteoclasts", Calcif Tissue Int, 70, pp.40~47 (2002)
31. Dixon R, "Bone turnover in elderly canine mandibles and tibia", J Dent Res, 76, pp.2579~ (1997)
32. Vignery A, "Dynamic histomorphometry of alveolar bone remodeling in the adult rat", Anat Rec, 196, pp.191~200 (1980)
33. Brunski JB, "In vivo bone response to biomechanical loading at the bone", dental-implant interface, 1999, pp.13, 99~119
34. Fournier P, "Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats", Cancer Res, 62, pp.6538~6544 (2002)
35. Reid IR, "bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity?", Bone, 41, pp.318~320 (2007)
36. Sawatari Y, "Bisphosphonates and bisphosphonate induced osteonecrosis", Oral Maxillofac Surg Clin North Am, 19, pp.487~498 (2007)
37. Hansen T, "James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis", J Oral Pathol Med, 35, pp.155~160 (2006)
38. Walter C, "Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis", Support Care Cancer, 15, pp.197~202 (2007)
39. Ficarra G, "Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment", J Clin Periodontol, 32, pp.1123~1128 (2005)
40. Marx RE, "Bisphosphonate-induced exposed bone (osteonecrosis", osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment, 2005, pp.63, 1567~1575
41. Bagan JV, "Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases", Oral Oncol, 42, pp.327~329 (2006)
42. Marx RE, "Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment", J Oral Maxillofac Surg, 65, pp.2397~2410 (2007)
43. Friberg B, "Branemark implants and osteoporosis: a clinical exploratory study", Clin Implant Dent Relat Res, 3, pp.50~56 (2001)
44. Rosen HN, "Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy", Calcif Tissue Int, 66, pp.100~103 (2000)
45. Schwartz JE, "Ask us: Some drugs affect tooth movement", Am J Orthod Dentofacial Orthop, 127, pp.644~ (2005)
46. Rinchuse DJ, "Orthodontic treatment of patients using bisphosphonates: a report of 2 cases", Am J Orthod Dentofacial Orthop, 131, pp.321~326 (2007)
47. Jeffcoat MK, "Safety of oral bisphosphonates: controlled studies on alveolar bone", Int J Oral Maxillofac Implants, 21, pp.349~353 (2006)
48. Wang HL, "Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report", J Periodontol, 78, pp.584~594 (2007)
49. review: bisphosphonates and osteonecrosis of the jaws, "Ann Intern Med", 2006, 753~761
50. IMS, "HEALTH" (2006), NPA Plus

관련 논문AI추천